Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
New England Journal of Medicine · 27.06.2024 · 390 (24) · 2239-2251
DOI: 10.1056/nejmoa2312282 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 27.06.2024. Verfasst von Mirna Chehade und 23 weiteren Autor:innen. Beteiligte Einrichtung: From the Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York (M.C.), and Regeneron Pharmaceuticals, Tarr…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Eosinophilic Esophagitis. Die Arbeit wurde bisher 151-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Regeneron Pharmaceuticals, Sanofi.
Abstract (Originalsprache)
BACKGROUND: Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including eosinophilic esophagitis in adults and adolescents. METHODS: In this phase 3 trial, we randomly assigned, in a 2:2:1:1 ratio, patients 1 to 11 years of age with active eosinophilic esophagitis who had had no response to proton-pump inhibitors to 16 weeks of a higher-exposure or lower-exposure subcutaneous dupilumab regimen or to placebo (two groups) (Part A). At the end of Part A, eligible patients in each dupilumab group continued the same regimen and those in the placebo groups were assigned to higher-exposure or lower-exposure dupilumab for 36 weeks (Part B). At each level of exposure, dupilumab was administered in one of four doses tiered according to baseline body weight. The primary end point was histologic remission (peak esophageal intraepithelial eosinophil count, ≤6 per high-power field) at week 16. Key secondary end points were tested hierarchically. RESULTS: In Part A, histologic remission occurred in 25 of the 37 patients (68%) in the higher-exposure group, in 18 of the 31 patients (58%) in the lower-exposure group, and in 1 of the 34 patients (3%) in the placebo group (difference between the higher-exposure regimen and placebo, 65 percentage points [95% confidence interval {CI}, 48 to 81; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York (M.C.), and Regeneron Pharmaceuticals, Tarrytown (R.L., E. Mortensen, A.S., E. McCann, M.A.K., M.P.K., J.D.H., C.…
ORCID-Profile: Matthew F Wipperman
Förderung
- Regeneron Pharmaceuticals
- Sanofi
Zitieren
APA
Chehade, M., Dellon, E. S., Spergel, J. M., Collins, M. H., Rothenberg, M. E., Pesek, R. D., Hirano, I., Liu, R., Laws, E., Mortensen, E., Martincova, R., Shabbir, A., McCann, E., Kamal, M. A., Kosloski, M. P., Hamilton, J. D., Samuely, C., Lim, W. K., Wipperman, M. F., …, & Maloney, J. (2024). Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. New England Journal of Medicine, 390(24), 2239-2251. https://doi.org/10.1056/nejmoa2312282
Vancouver
Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. New England Journal of Medicine. 2024;390(24):2239-2251. doi:10.1056/nejmoa2312282
BibTeX
@article{Chehade2024,
author = {Chehade, Mirna and Dellon, Evan S and Spergel, Jonathan M and Collins, Margaret H and Rothenberg, Marc E and Pesek, Robert D and Hirano, Ikuo and Liu, Ruiqi and Laws, Elizabeth and Mortensen, Eric and Martincova, Renata and Shabbir, Arsalan and McCann, Eilish and Kamal, Mohamed A and Kosloski, Matthew P and Hamilton, Jennifer D and Samuely, Carin and Lim, Wei Keat and Wipperman, Matthew F and Farrell, Annamaria and Patel, Naimish and Yancopoulos, George D and Glotfelty, Lila and Maloney, Jennifer},
title = {Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {24},
pages = {2239--2251},
doi = {10.1056/nejmoa2312282}
}
EUVIMED